Effect of body mass index on the ED50 volume of bupivacaine 0.5% for supraclavicular brachial plexus block

The aim of this study was to determine whether the ED50 dose of bupivacaine 0.5% for supraclavicular brachial plexus block increases with increasing body mass index (BMI). This double-blind, non-randomized trial followed an up-and-down sequential allocation design. Adult patients undergoing elective...

Full description

Saved in:
Bibliographic Details
Published in:British journal of anaesthesia : BJA 2010-04, Vol.104 (4), p.490-495
Main Authors: Gupta, P.K., Pace, N.L., Hopkins, P.M.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
anaesthesia
anaesthesia, conduction
anaesthetic techniques
anaesthetic techniques, regional, brachial plexus
anaesthetics local
anaesthetics local, bupivacaine
Anesthesia
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Anesthetics, Local - administration & dosage
Anesthetics, Local - pharmacology
Biological and medical sciences
Body Mass Index
brachial plexus
Brachial Plexus - drug effects
Brachial Plexus - ultrastructure
bupivacaine
Bupivacaine - administration & dosage
Bupivacaine - pharmacology
conduction
Dose-Response Relationship, Drug
dose–response relationship
Double-Blind Method
drug
Female
Humans
Male
Medical sciences
Middle Aged
Nerve Block - methods
regional
ultrasonography
Ultrasonography, Interventional
Upper Extremity - surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to determine whether the ED50 dose of bupivacaine 0.5% for supraclavicular brachial plexus block increases with increasing body mass index (BMI). This double-blind, non-randomized trial followed an up-and-down sequential allocation design. Adult patients undergoing elective upper limb surgery under ultrasound-guided supraclavicular brachial block were recruited. A preliminary study was used to guide the dosing schedule for the main study in which patients were divided into three groups according to their BMI (Group A, BMI >27 kg m−2; Group B, BMI 24–27 kg m−2; Group C, BMI
ISSN:0007-0912
1471-6771
DOI:10.1093/bja/aeq017